Showing results (1981-1990 of 2,286) with videos related to
Sort By:
Pageof 229
Journal of Neuro-Oncology|October 15, 2011
Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patientsDavid A Reardon, James E Herndon, Katherine Peters, et al.Annual Review of Marine Science|July 2, 2013
Climate change influences on marine infectious diseases: implications for management and societyColleen A Burge, C Mark Eakin, Carolyn S Friedman, et al.American Journal of Veterinary Research|December 3, 2009
Identification of variables that optimize isolation and culture of multipotent mesenchymal stem cells from equine umbilical-cord bloodElizabeth M Schuh, Michael S Friedman, Danielle D Carrade, et al.Journal of Pediatric Hematology/Oncology|June 11, 1999
Cyclophosphamide for the treatment of progressive low-grade astrocytoma: a Pediatric Oncology Group phase II StudyR P Kadota, L E Kun, J W Langston, et al.British Journal of Cancer|July 3, 2008
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugsD M Ashley, C D Riffkin, M M Lovric, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastomaJames J Vredenburgh, Annick Desjardins, David A Reardon, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Phase II trial of bevacizumab and irinotecan in recurrent malignant gliomaJames J Vredenburgh, Annick Desjardins, James E Herndon, et al.Molecular Cancer Therapeutics|October 15, 2009
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiformeJohn H Sampson, Gary E Archer, Duane A Mitchell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumabEvelyn Yao, Wei Zhou, Si Tuen Lee-Hoeflich, et al.Cancer Chemotherapy and Pharmacology|March 7, 2012
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patientsDavid A Reardon, Charles A Conrad, Timothy Cloughesy, et al.Pageof 229